The HDHD5 Knockout 143B Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from the human 143B osteosarcoma cell line. This product features targeted disruption of the HDHD5 gene, which encodes a putative haloacid dehalogenase-type hydrolase. The polyclonal nature arises from a mixed genotype of editing outcomes, providing a pooled loss-of-function model that captures diverse mutational events without the uniformity of a clonal line. By abolishing functional HDHD5 expression in a fraction of cells, this resource facilitates genotype-phenotype correlation studies under controlled experimental conditions.
The 143B cell line is a well-characterized human osteosarcoma model originally derived from a bone tumor biopsy. Notably, these cells are thymidine kinase-deficient (TK-), a trait that has been extensively exploited in cybrid generation for mitochondrial disease research, where they are fused with patient-derived mitochondria to study mitochondrial-nuclear interactions. As a cancer cell line, 143B exhibits aggressive proliferation, anchorage-independent growth, and invasive capacity, making it a pertinent system for investigating tumor cell biology and metabolic adaptations. Its robust growth characteristics and genetic manipulability further enhance its utility in functional genomics.
HDHD5 is predicted to belong to the haloacid dehalogenase superfamily, functioning as a hydrolase that potentially cleaves phosphate ester bonds within metabolic intermediates. Although its specific substrates and regulatory partners remain unidentified, the enzyme is hypothesized to participate in phosphate metabolism and cellular detoxification processes. Disruption of HDHD5 via CRISPR/Cas9 is expected to impair its hydrolase activity, which could perturb phosphate homeostasis and related metabolic pathways. The lack of known upstream regulators or downstream effectors underscores the value of this knockout model for de novo discovery of HDHD5??s molecular network.
In the 143B osteosarcoma background, HDHD5 knockout provides a unique opportunity to explore its contribution to cancer cell physiology. Given the metabolic reprogramming inherent to malignant transformation, alterations in phosphate metabolism may influence signaling cascades, nucleotide synthesis, and redox balance. Furthermore, the chromosomal location of HDHD5 near the cat eye syndrome critical region suggests its involvement in developmental gene dosage effects; this model therefore also serves as a tool for studying such anomalies in a neoplastic context. The 143B line??s compatibility with mitochondrial exchange further permits analysis of potential nuclear-mitochondrial interplay involving HDHD5.
Researchers can employ these polyclonal knockout cells in a variety of functional assays to dissect HDHD5 biology. Western blotting and RT-qPCR are recommended to confirm gene disruption, while phosphatase activity assays can directly measure hydrolase function. Cancer-relevant phenotypes such as proliferation, migration, and invasion can be assessed to evaluate effects on tumor malignancy. Additionally, the model is applicable to cat eye syndrome gene dosage studies, where altered HDHD5 levels may contribute to developmental pathologies. For expert support on experimental design or product specifications, please contact Ascent Research.
